Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Current Liabilities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Total Current Liabilities for 15 consecutive years, with $743.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 46.43% year-over-year to $743.4 million, compared with a TTM value of $743.4 million through Dec 2025, up 46.43%, and an annual FY2025 reading of $743.4 million, up 46.43% over the prior year.
  • Total Current Liabilities was $743.4 million for Q4 2025 at Neurocrine Biosciences, up from $638.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $743.4 million in Q4 2025 and bottomed at $190.0 million in Q1 2021.
  • Average Total Current Liabilities over 4 years is $479.9 million, with a median of $515.3 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities crashed 63.03% in 2021, then soared 48.48% in 2025.
  • Year by year, Total Current Liabilities stood at $225.9 million in 2021, then skyrocketed by 189.86% to $654.8 million in 2023, then decreased by 22.46% to $507.7 million in 2024, then skyrocketed by 46.43% to $743.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for NBIX at $743.4 million in Q4 2025, $638.0 million in Q3 2025, and $546.3 million in Q2 2025.